🇺🇸 FDA
Pipeline program

CEP-33457

C33457/2047

Phase 3 small_molecule completed

Quick answer

CEP-33457 for Systemic Lupus Erythematosus is a Phase 3 program (small_molecule) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 2 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
Systemic Lupus Erythematosus
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials